220 related articles for article (PubMed ID: 21725611)
21. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
22. Expression and function of RANK in human monocyte chemotaxis.
Mosheimer BA; Kaneider NC; Feistritzer C; Sturn DH; Wiedermann CJ
Arthritis Rheum; 2004 Jul; 50(7):2309-16. PubMed ID: 15248232
[TBL] [Abstract][Full Text] [Related]
23. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
24. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
Jallal H; Valentino ML; Chen G; Boschelli F; Ali S; Rabbani SA
Cancer Res; 2007 Feb; 67(4):1580-8. PubMed ID: 17308097
[TBL] [Abstract][Full Text] [Related]
25. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
26. Role of non-receptor and receptor tyrosine kinases (TKs) in the antitumor action of alpha-difluoromethylornithine (DFMO) in breast cancer cells.
Xu H; Washington S; Verderame MF; Manni A
Breast Cancer Res Treat; 2008 Nov; 112(2):255-61. PubMed ID: 18097746
[TBL] [Abstract][Full Text] [Related]
27. Carbonic anhydrase XII promotes invasion and migration ability of MDA-MB-231 breast cancer cells through the p38 MAPK signaling pathway.
Hsieh MJ; Chen KS; Chiou HL; Hsieh YS
Eur J Cell Biol; 2010 Aug; 89(8):598-606. PubMed ID: 20434230
[TBL] [Abstract][Full Text] [Related]
28. CD24 enhances DNA damage-induced apoptosis by modulating NF-κB signaling in CD44-expressing breast cancer cells.
Ju JH; Jang K; Lee KM; Kim M; Kim J; Yi JY; Noh DY; Shin I
Carcinogenesis; 2011 Oct; 32(10):1474-83. PubMed ID: 21798852
[TBL] [Abstract][Full Text] [Related]
29. OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation.
Tat SK; Padrines M; Theoleyre S; Couillaud-Battaglia S; Heymann D; Redini F; Fortun Y
Bone; 2006 Oct; 39(4):706-15. PubMed ID: 16750945
[TBL] [Abstract][Full Text] [Related]
30. Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors.
Amemiya Y; Yang W; Benatar T; Nofech-Mozes S; Yee A; Kahn H; Holloway C; Seth A
Breast Cancer Res Treat; 2011 Apr; 126(2):373-84. PubMed ID: 20464481
[TBL] [Abstract][Full Text] [Related]
31. Src and Cas are essentially but differentially involved in angiotensin II-stimulated migration of vascular smooth muscle cells via extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase activation.
Kyaw M; Yoshizumi M; Tsuchiya K; Kagami S; Izawa Y; Fujita Y; Ali N; Kanematsu Y; Toida K; Ishimura K; Tamaki T
Mol Pharmacol; 2004 Apr; 65(4):832-41. PubMed ID: 15044612
[TBL] [Abstract][Full Text] [Related]
32. Arachidonic acid induces an increase of β-1,4-galactosyltransferase I expression in MDA-MB-231 breast cancer cells.
Villegas-Comonfort S; Serna-Marquez N; Galindo-Hernandez O; Navarro-Tito N; Salazar EP
J Cell Biochem; 2012 Nov; 113(11):3330-41. PubMed ID: 22644815
[TBL] [Abstract][Full Text] [Related]
33. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.
Ikeda F; Matsubara T; Tsurukai T; Hata K; Nishimura R; Yoneda T
J Bone Miner Res; 2008 Jun; 23(6):907-14. PubMed ID: 18251700
[TBL] [Abstract][Full Text] [Related]
34. Cdc42 negatively regulates intrinsic migration of highly aggressive breast cancer cells.
Zuo Y; Wu Y; Chakraborty C
J Cell Physiol; 2012 Apr; 227(4):1399-407. PubMed ID: 21618528
[TBL] [Abstract][Full Text] [Related]
35. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway.
Panizo S; Cardus A; Encinas M; Parisi E; Valcheva P; López-Ongil S; Coll B; Fernandez E; Valdivielso JM
Circ Res; 2009 May; 104(9):1041-8. PubMed ID: 19325147
[TBL] [Abstract][Full Text] [Related]
36. Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion.
Krueger JS; Keshamouni VG; Atanaskova N; Reddy KB
Oncogene; 2001 Jul; 20(31):4209-18. PubMed ID: 11464287
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
[TBL] [Abstract][Full Text] [Related]
38. Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo.
Kurio N; Shimo T; Fukazawa T; Takaoka M; Okui T; Hassan NM; Honami T; Hatakeyama S; Ikeda M; Naomoto Y; Sasaki A
Exp Cell Res; 2011 May; 317(8):1134-46. PubMed ID: 21338601
[TBL] [Abstract][Full Text] [Related]
39. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells.
Gilad LA; Bresler T; Gnainsky J; Smirnoff P; Schwartz B
J Endocrinol; 2005 Jun; 185(3):577-92. PubMed ID: 15930183
[TBL] [Abstract][Full Text] [Related]
40. Carvedilol suppresses migration and invasion of malignant breast cells by inactivating Src involving cAMP/PKA and PKCδ signaling pathway.
Dezong G; Zhongbing M; Qinye F; Zhigang Y
J Cancer Res Ther; 2014; 10(4):998-1003. PubMed ID: 25579542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]